Drug intelligence / Profile preview

FortiVac

Development stage: Preclinical
Lead developer: Multimeric Biotherapeutics
Modality: Vaccines & Immunotherapeutics

Overview

FortiVac is an immunostimulant drug candidate initially developed by Multimeric Biotherapeutics. It is being investigated as a vaccine, with its highest global R&D status reported as preclinical. The specific mechanism of action, molecular targets, and detailed composition have not been disclosed in public sources. Its primary indication appears to be for immunization or immune system stimulation, but no further clinical details are available at this stage[1].

Brand names: FortiVac
Other names: FortiVac

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on FortiVac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FortiVac.

Explore the full profile